As reported in Korea Biomedical Review, Lilly Korea is conducting a clinical trial on rheumatoid arthritis drug Olumiant (baricitinib) to test whether it will be effective for alopecia areata—spot baldness. Recently, the Korean Ministry of Food and Drug Safety approved the industry sponsor to proceed with a multicenter, randomized, double-blind, placebo-controlled Phase 2/3 trial on barictinib. The study will focus on patients with severe or very severe alopecia areata.
This global study will occur in Korea. Participating research sites include:
- Catholic University of Korea St. Paul’s Hospital
- Gangdong Kyung Hee University Hospital
- Konkuk University Hospital
- Kyungpook National University Hospital
- Pusan National University Hospital
- Seoul National University Bundang Hospital
- Seoul National University Hospital, Inha University Hospital
- Chonbuk National University Hospital
- Chung-Ang University Hospital
- Chungnam National University Hospital
Olumiant (baricitinib) is a Janus kinase (JAK) 1/2 inhibitor that suppresses the increase of inflammatory cytokine by blocking intercellular communication paths of JAK. The treatment was approved by FDA and Korean authority. Pfizer’s Xeljaz is leading the oral rheumatoid arthritis drug market. However, Olumiant can be taken once daily while Xeljanz must be taken twice a day.